Johnson & Johnson (JNJ) Treasury Shares (2009 - 2026)
Johnson & Johnson (JNJ) posted Treasury Shares of $75.9 billion for Q2 2026, down 0.53% sequentially from $76.3 billion in Q1 2026, and up 3466.67% YoY from $2.1 billion in Q2 2025.
Johnson & Johnson (JNJ) Treasury Shares (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Treasury Shares for 18 years, with the latest figure at $75.9 billion in Q2 2026.
- Quarterly Treasury Shares rose 3466.67% year-over-year to $75.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $75.9 billion (up 3466.67% YoY) and the FY2025 annual result came in at $75.6 billion, changed 0.07% from the prior year.
- Treasury Shares fell to $75.9 billion in Q2 2026 per JNJ's latest filing, from $76.3 billion in the prior quarter.
- Over five years, Treasury Shares peaked at $714.2 million in Q1 2025 and troughed at $490.5 million in Q2 2022.
- A 5-year average of $635.8 million and a median of $712.5 million in 2024 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2024 and 2026: Treasury Shares plunged 96.53% in 2024, then surged 3482.15% in 2026.
- Over 5 years, Treasury Shares stood at $2.2 billion in 2022, then jumped by 3394.78% to $75.7 billion in 2023, then gained by 0.02% to $75.7 billion in 2024, then retreated by 0.07% to $75.6 billion in 2025, then climbed by 0.32% to $75.9 billion in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $75.9 billion, $76.3 billion, and $75.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 75.86 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 49.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.19 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 711.62 Mn |
| Jun 28, 2026 | 75.86 Bn |
| Jun 28, 2026 | 711.62 Mn |
| Jun 28, 2026 | 75.86 Bn |
| Mar 29, 2026 | 713.26 Mn |
| Mar 29, 2026 | 76.26 Bn |
| Mar 29, 2026 | 76.26 Bn |
| Mar 29, 2026 | 713.26 Mn |
| Dec 28, 2025 | 75.62 Bn |
| Dec 28, 2025 | 75.62 Bn |
| Dec 28, 2025 | 711.90 Mn |
| Dec 28, 2025 | 711.90 Mn |
| Sep 28, 2025 | 75.89 Bn |
| Sep 28, 2025 | 713.65 Mn |
| Sep 28, 2025 | 713.65 Mn |
| Sep 28, 2025 | 75.89 Bn |
| Jun 29, 2025 | 713.06 Mn |
| Jun 29, 2025 | 2.13 Bn |
| Jun 29, 2025 | 2.13 Bn |
| Jun 29, 2025 | 713.06 Mn |